Cerluten
CNS peptide bioregulator
Cerluten is a CNS peptide complex. Searched under its trade name, it has no indexed literature at all — and saying so plainly is more useful than the paragraph of hedged mechanism language that usually fills the space.
Cerluten quick facts
| Reported research dose (Injectable) | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~15-30 min |
| Forms | Injectable, Oral |
| Evidence level | Russian studies; limited |
| Other forms available | Oral — dosed differently |
The CNS Khavinson peptide — course-based neuro support. The CNS peptide of the group, usually run for cognitive rather than longevity reasons. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, nothing on a blood panel will tell you — use a fixed cognitive task and your own sleep quality, measured the same way each time. Run it as an experiment you measure, not a protocol you trust.
What Cerluten actually is — and why that changes the mechanism
Cerluten is a CNS peptide complex — a brain-tissue extract, not a molecule. No sequence, no mass, no structure to model, and no published identification of any component by mass spectrometry.
The mechanism claim is entirely borrowed. What gets written about Cerluten is the class story: short peptides enter the nucleus and modulate gene transcription. That argument was constructed for defined two-to-four-residue molecules, and it depends on the specific chemistry of individual side chains — computed groove interactions, charge, the energetics of particular contacts. None of that reasoning survives being applied to a mixture whose contents are unpublished. The mechanism section on most pages about this compound is describing molecules nobody has shown are in the bottle.
What is honestly left. A brain-derived peptide fraction with a neurotrophic rationale and no molecular identity, sold on a mechanism imported from a different literature. That is a weaker position than its nearest neighbor Cortexin occupies, and the difference is worth understanding before choosing between them.
What the primary literature on Cerluten actually says
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
The nearest thing to relevant evidence, and it is about the class rather than this product: an independent review of animal-derived nootropics found risk of bias moderate to high and certainty of evidence low to very low across everything it could locate. Cerluten was not among the products it located.
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The class mechanism claim — short peptides in the nucleus modulating transcription — which is what a CNS complex is sold on.
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
Why the route is what it is: a peptide complex is not a PEPT1 substrate.
What is not here. Nothing is indexed under the trade name Cerluten. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Cerluten evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Cerluten. There is nothing to tear down, and that is the finding. A search of Europe PMC and PubMed under the trade name returns no trial, no animal study and no mechanism paper. What exists is a product, a tissue of origin, and a class-level hypothesis. Read next to Cortexin — same organ system, one indexed trial — the difference between the two is the difference between thin evidence and none.
What the data does support: nothing published under this name. Nothing is indexed for Cerluten — no trial, no animal study, no mechanism paper. That sentence is the honest headline and most write-ups bury it.
The nearest relevant evidence is about the class, not the product. Alsulaimani and Quinn's independent systematic review of animal-derived nootropics covered 24 randomized trials and 2,245 participants across Cerebrolysin, Actovegin and Cortexin, and concluded that “risk of bias was moderate to high, there was imprecision, and certainty of evidence was considered low to very low”, with effects “modest and probably less than would be considered clinically relevant”. Cerluten was not among the products they located. So even the class-level evidence is evidence about other products.
The specific epistemic position, stated exactly. This is not a compound whose trials failed. It is a compound with no trials — an absence of evidence, not evidence of absence. But an absence this complete means there is nothing here to reason from except the class rationale, and a reader should weigh it accordingly rather than reading the class's better members' data onto it.
What is actually measured, and what is not. This CNS complex has no trial, no effect size and no usable p-value under its own name. No animal experiment has been published on it. No cell-culture readout exists for the fraction. Its pharmacokinetic profile has never been studied in any species. The half-life of its peptide components is unknown. Nobody has quantified how quickly it clears. Whether a peptidase degrades it before it acts has never been tested. No transcription measurement has been reported under this preparation. Nobody has demonstrated a component entering a nuclear compartment. Unlike Cortexin, it did not appear at all in the 2021 independent review of 24 trials in this drug class.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Cerluten pharmacokinetics — how much of it actually gets in
Why there is no half-life. A half-life describes one compound. This is a mixture, so the quick-facts figure of “~15-30 min” is a number for an unspecified something. No human pharmacokinetic study of this preparation exists.
What can still be reasoned. Serum aminopeptidases degrade short peptide components in minutes. That is not an objection to the mechanism — a trophic or transcriptional signal outlives the molecule that started it — but it does mean serum measurement is uninformative and the only meaningful measurements are downstream of the effect.
Route, and the contradiction in it. Cerluten is sold here in both injectable and oral form. An injection is 100% bioavailable by definition, bypassing gastric acid, pancreatic proteases, the brush-border peptidase layer and hepatic first-pass altogether. The only named mechanism by which an intact peptide crosses the gut wall is PEPT1, which carries di- and tripeptides — a peptide complex of unknown chain length is not a PEPT1 substrate. Selling the same preparation by two routes at comparable reference amounts implies the two deliver comparable exposure, and they cannot. At least one of those two figures is inherited rather than derived.
And the step upstream of everything. The target is brain. No study has measured whether anything in this preparation crosses the blood-brain barrier by any route. Every downstream claim depends on a step for which there is no data at all.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Cerluten to work
What would have to be true. The complex would have to contain biologically active peptides — unpublished; those would have to survive administration — unmeasured; cross the blood-brain barrier — never examined; and change cognition or neurological function measurably. Four steps, and unlike the rest of this cohort not one of them has been addressed for this specific product.
With no product-specific literature at all, the only responsible predictions are the ones a user could check themselves.
- Prediction 1 — MoCA. should improve against a control arm if the class claim is real, over a course. Same instrument as Cortexin, deliberately: the comparison between the two products is the only experiment here that would tell you anything.
- Prediction 2 — hs-CRP (High-Sensitivity C-Reactive Protein). should not rise, within a course. A safety readout for an injected tissue preparation.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Cerluten did to it — and that difference is the entire point of testing.
Cerluten versus the alternatives
Cerluten versus Cortexin. Both are CNS peptide complexes with no molecular identity, sold for overlapping goals, at similar prices. The difference is decisive and almost never stated: an independent group outside Russia located a randomized trial of Cortexin and graded it. They located nothing for Cerluten. If you are choosing between the two on evidence rather than on marketing, that is the whole answer.
Cerluten versus Pinealon is the extract-versus- peptide trade in its usual form: Pinealon has a sequence, a computable mass, a verifiable purity number and a dedicated mechanism review with animal data; Cerluten has none of those and no clinical record either.
And against the credible alternative. For cognition and neurological ageing the interventions with human outcome data are blood pressure control, hearing correction, exercise, sleep and treating depression. They are unglamorous and they have trials. On evidence this is not a close comparison, and the only coherent reason to be on this page is that the proven things are already handled.
What you are actually buying when you buy Cerluten
Cerluten is an extract, not a molecule, and for this product that matters more than for most, because there is nothing else to hold on to. A certificate of analysis can confirm sterility, endotoxin, total protein and the absence of named contaminants. It cannot confirm identity — there is no formula to check against, and the product is defined by its process rather than by a structure. Two vials with clean certificates can hold different mixtures.
With no published trial, no published composition and no assay that distinguishes one CNS complex from another, there is no document a buyer can ask for that would establish what this product is. That is not an accusation about any vendor. It is a structural fact about extracts, and it is the most important thing on this page.
Extract rules apply, with one addition: where a product has no published literature under its own name, the vendor's process description is the entire basis for believing it is what it says. Ask for it in writing.
Where to get Cerluten
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Cerluten
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold for cognitive and neurological support, typically in oral courses of 10–20 days. Used as the 'natural' counterpart to Pinealon and Cortagen.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A brain-tissue peptide complex proposed to support neuronal protein synthesis. Same category as Cerebrolysin and Cortexin — a preparation defined by its source and process rather than its contents.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- The blood-brain barrier is the unaddressed step. Cerebrolysin and Cortexin are injected; this is sold orally, which requires a peptide mixture to survive the gut and then cross into the brain. Neither has been shown.
What that tier rests on here. The tier above is class inference, not product data. Nothing is indexed under the trade name Cerluten, and the independent review of this drug class did not locate this product at all.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
The awkward fact about Cerluten is that a better-documented product is made from the same tissue. Cortexin is a cerebral cortex polypeptide preparation with a measured brain penetration figure, a receptor-binding panel and a head-to-head animal comparison against two competitors, all in one open-access paper Kurkin 2021. Cerluten is a central-nervous-system peptide complex with none of those. Same class, same city of origin, same tissue — and one of them has been through an experiment.
What exists at the class level, and what it is worth. Ryzhak 2015 compared seven calf-tissue extracts in organotypic culture, cortex among them, and reported effects on explant growth by donor age. Khavinson 2012 is the tissue-specificity claim in its general form. Khavinson 2021 takes defined tripeptides, not extracts, into a mouse model of Alzheimer's disease. All of that is upstream of a brain in a person by several steps, and every step is unmeasured for this product.
Human evidence: zero, and the grading of the neighborhood is poor. Alsulaimani 2021 pooled the trials of animal-derived nootropics as a category and graded certainty low. Nothing in that pool is Cerluten. A search of NCBI PubTator3 on 6 September 2026 returned no record with this trade name in it, in any language.
The transport step is a docking score. Khavinson 2022 models peptide carriage on PEPT1, PEPT2, LAT1 and LAT2, computationally. For an extract the question does not even parse: a mixture has no single molecule to dock.
What nobody has tested yet
Run Cerluten in the assay Cortexin already passed. The middle cerebral artery occlusion model, the adhesive removal test, the rotarod, the Morris water maze and the receptor panel are all published in enough detail to copy exactly. Adding one arm to an existing protocol is the cheapest informative experiment available to this product, and it would say within one study whether the two preparations are equivalent or whether one of them is inert.
Nobody has compared the two vials analytically. If Cerluten and Cortexin are both cortex-derived polypeptide fractions, a side-by-side chromatogram would show whether they are the same product under two labels. That is one afternoon of instrument time and it has never been published.
Extrapolation, labeled as such. If the mechanism behind Cortexin's animal results is glutamate-receptor binding rather than gene regulation, then any cortex extract prepared the same way should share it, and Cerluten would work for a reason its own marketing never claims. That is a testable and slightly deflating hypothesis: the product might be real and the story about why might be wrong.
Sources read for this page
- Kurkin DV. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One 2021 · PMID 34260655
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
- Khavinson V. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel) 2021 · PMID 34071923
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
Cerluten — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Cerluten — safety specifics for this compound
Specific to Cerluten: this is an animal brain-tissue derivative, which is the most conservative-handling category in this cohort — animal-source biologics carry protein-allergy and immunogenicity considerations that synthetic peptides do not, and nervous-tissue sourcing has historically attracted more scrutiny than other tissues. There is no reported safety signal for this product. There is also no safety study, which is a different statement. The one independent read of this class — Alsulaimani and Quinn, 24 randomized trials, n=2,245 across them — located none of Cerluten, so the “no safety concerns” line quoted for the class was measured on other compounds entirely. That absence has a number attached: 0 trials, 0 animal studies and 0 mechanism papers are indexed under this name, so no dose has been given to any human under observation and written down. Every tolerability claim made for it is a claim about the class, measured on Cerebrolysin and Actovegin. Brain-tissue sourcing is also the one category in this cohort where provenance is a safety question in its own right, and the preparation's contents are unpublished.
Cerluten — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Cerluten moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Cerluten in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Cerluten
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Cerluten — frequently asked questions
Is Cerluten a peptide or an extract?
An extract — a peptide complex from central nervous system, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Cerluten?
Nothing is indexed under the trade name Cerluten.
What should I measure if I run Cerluten?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M — Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
Cerluten inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Cerluten is used for
Cerluten appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Cerluten is the pineal & brain arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.